Files
Abstract
A barrier in designing safer CB1R drugs is our lack of understanding the circuit and tissue-specific involvement of AEA and THC in different CB1R-mediated pathologies, which is compounded by their physiochemical properties as cannabinoids. Here we develop two photopharmacological tools with THC and AEA to overcome current limitations in the application of cannabinoid ligands and advance our ability to optically control CB1R on select cells.